Literature DB >> 20650641

Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors.

Afshin Zarghi1, Razieh Ghodsi.   

Abstract

A new series of ketoprofen analogs were synthesized to evaluate their biological activities as selective cyclooxygenase-2 (COX-2) inhibitors. In vitro COX-1 and COX-2 inhibition studies showed that all compounds were potent and selective inhibitors of the COX-2 isozyme with IC(50) values in the highly potent 0.057-0.085 microM range, and COX-2 selectivity indexes in the 115 to >1298.7 range. Compounds possessing azido pharmacophore group (8a and 8b) exhibited highly COX-2 inhibitory selectivity and potency even more than reference drug celecoxib. Molecular modeling studies indicated that the azido substituent can be inserted deeply into the secondary pocket of COX-2 active site for interactions with Arg(513). Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20650641     DOI: 10.1016/j.bmc.2010.06.094

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  12 in total

1.  Anti-quorum sensing potential of ketoprofen and its derivatives against Pseudomonas aeruginosa: insights to in silico and in vitro studies.

Authors:  Amineh Sadat Tajani; Elham Jangi; Maryam Davodi; Sima Golmakaniyoon; Razieh Ghodsi; Vahid Soheili; Bibi Sedigheh Fazly Bazzaz
Journal:  Arch Microbiol       Date:  2021-07-28       Impact factor: 2.552

2.  Synthesis and biological evaluation of RGD conjugated with Ketoprofen/Naproxen and radiolabeled with [99mTc] via N4(GGAG) for αVβ3 integrin-targeted drug delivery.

Authors:  Reza Mohammadi; Bahareh Shokri; Danial Shamshirian; Afshin Zarghi; Soraya Shahhosseini
Journal:  Daru       Date:  2019-12-16       Impact factor: 3.117

3.  Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships.

Authors:  Afshin Zarghi; Sara Arfaei
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

4.  Pharmacological effects of a synthetic quinoline, a hybrid of tomoxiprole and naproxen, against acute pain and inflammation in mice: a behavioral and docking study.

Authors:  Hossein Hosseinzadeh; Fatemeh Mazaheri; Razieh Ghodsi
Journal:  Iran J Basic Med Sci       Date:  2017-04       Impact factor: 2.699

5.  Design, synthesis and biological evaluation of novel benzodioxole derivatives as COX inhibitors and cytotoxic agents.

Authors:  Mohammed Hawash; Nidal Jaradat; Saba Hameedi; Ahmed Mousa
Journal:  BMC Chem       Date:  2020-09-07

6.  Design, Synthesis and Biological Evaluation of4-(Imidazolylmethyl)-2-(4-methylsulfonyl phenyl)-Quinoline Derivatives as Selective COX-2 Inhibitors and In-vitro Anti-breast Cancer Agents.

Authors:  Razieh Ghodsi; Ebrahim Azizi; Afshin Zarghi
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

7.  Physicochemical, Stress Degradation Evaluation and Pharmacokinetic Study of AZGH101; a New Synthesized COX2 Inhibitor after I.V. and Oral Administration in Male and Female Rats.

Authors:  Hoda Bahmanof; Simin Dadashzadeh; Afshin Zarghi; Alireza Shafaati; Seyed Mohsen Foroutan
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

8.  Physicochemical, Stress Degradation Evaluation and Pharmacokinetic Study of AZGH102, a New Synthesized COX2 Inhibitors after I.V. and Oral Administration in Male and Female Rats.

Authors:  Hoda Bahmanof; Simin Dadashzadeh; Afshin Zarghi; Alireza Shafaati; Seyed Mohsen Foroutan
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

9.  7-Hydroxy-4-phenyl-1, 2-dihydroquinoline derivatives: synthesis via one-pot, three-component reaction and structure elucidation.

Authors:  Rukhsana Tabassum; Muhammad Ashfaq; Hiroyuki Oku
Journal:  Heliyon       Date:  2020-10-01

10.  Potential antibacterial and antifungal activities of novel sulfamidophosphonate derivatives bearing the quinoline or quinolone moiety.

Authors:  Ismahene Bazine; Samira Bendjedid; Abbes Boukhari
Journal:  Arch Pharm (Weinheim)       Date:  2020-12-07       Impact factor: 4.613

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.